Drug Profile
RBx 6198
Latest Information Update: 21 Oct 2008
Price :
$50
*
At a glance
- Originator Ranbaxy Laboratories
- Class
- Mechanism of Action Alpha-1a adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia
Most Recent Events
- 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo Company
- 07 Aug 2002 Preclinical trials in Benign prostatic hyperplasia in India (unspecified route)